Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

@article{Hoyle2013CosteffectivenessOC,
  title={Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.},
  author={Martin Hoyle and Jaime L Peters and Louise Crathorne and Tracey Jones-Hughes and Chris Cooper and Mark Napier and Chris Hyde},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2013},
  volume={16 2},
  pages={
          288-96
        }
}
  • M. Hoyle, J. Peters, +4 authors C. Hyde
  • Published 2013
  • Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
OBJECTIVES To estimate the cost-effectiveness of cetuximab monotherapy, cetuximab plus irinotecan, and panitumumab monotherapy compared with best supportive care (BSC) for the third and subsequent lines of treatment of patients with Kirsten rat sarcoma wild-type metastatic colorectal cancer from the perspective of the UK National Health Service. METHODS An "an area under the curve" cost-effectiveness model was developed. The clinical effectiveness evidence for both cetuximab and panitumumab… Expand
RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources.
TLDR
RAS testing with cetuximab treatment is likely to be cost-effective for patients with metastatic colorectal cancer when PAP is available in China, and one-way sensitivity analyses showed that the median overall survival time for the cetUXimab was the most influential parameter. Expand
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer
TLDR
A pricing framework for new anticancer drugs to reflect the economics of drugs is established in China by constructing two pricing scenarios for panitumumab and estimating the cost-effectiveness of this intervention from the perspective of Chinese health care systems. Expand
Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
TLDR
Results of this cost-effectiveness analysis showed that third-line treatment with cetuximab for patients with KRAS (exon 2) wt mCRC offered clinical benefits at additional cost. Expand
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
TLDR
FOLFIRI + cetuximab is cost-effective compared with FOLFIRi’+’bevacizumab in patients with RAS wt mCRC, with ICERs well below willingness-to-pay thresholds for diseases with a high burden. Expand
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
TLDR
This study found that doublet therapy for metastatic BRAF variant colorectal cancer was unlikely to be cost-effective under current pricing and cost-effectiveness needs to be considered in clinical trial design. Expand
COST-EFFECTIVENESS ANALYSIS OF SELECTIVE 1ST-LINE BIOLOGICS FOR wtRAS
Background Evidence from a retrospective analysis of multiple large phase iii trials suggested that primary tumour location (ptl) in RAS wild-type metastatic colorectal cancer (wtRAS mcrc) might haveExpand
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
TLDR
TAS-102 and bevacizumab combination therapy is a cost-effective option for patients who have metastatic colorectal cancer in the Japanese health care system at a willingness-to-pay of under $50,000 per QALY gained. Expand
Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
TLDR
Anti-EGFR therapy is more cost-effective than Bev as a first-line targeted therapy in left-sided pan-RAS WT and pan- RAS WT, with ICER. Expand
Cost‐effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
TLDR
Based on the results of the analysis, trifluridine/tipiracil offers an important new treatment option for patients with mCRC maintaining good performance status at the end of life, and is shown to dominate regorafenib (improve outcomes with reduced costs). Expand
Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
TLDR
Panitumumab can lower the cost of care without impacting outcomes in chemo-refractory metastatic CRC settings and provides a strong argument to consider panitumUMab in lieu of cetuximab in these patients. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 20 REFERENCES
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
TLDR
The incremental cost per life-year gained for cetuximab/irinotecan is relatively high compared with other health-care interventions, however, this result should be considered in the context of a number of factors specific to the treated patient population. Expand
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisa
TLDR
Investigation of the clinical effectiveness and cost-effectiveness of panitumumab monotherapy and cetuximab (mono- or combination chemotherapy) for Kirsten rat sarcoma (KRAS) wild-type (WT) patients, and bevacizumab in combination with non-oxaliplatin chemotherapy, for the treatment of metastatic colorectal cancer after first-line chemotherapy. Expand
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
TLDR
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer. Expand
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
TLDR
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated. Expand
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
TLDR
The incremental cost-effectiveness ratio of cetuximab over best supportive care alone in unselected advanced colorectal cancer patients is high and sensitive to drug cost. Expand
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
TLDR
This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that. Expand
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
TLDR
Both nilotinib and dasatinib are highly unlikely to be cost-effective versus interferon-α for people intolerant to imatinib and both drugs represent poor value for money for a range of plausible structural assumptions. Expand
KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
TLDR
Despite substantial costs of predictive testing, it is economically favorable to identify patients with KRAS and BRAF wild-type status, and new predictive tests for KRASand BRAF status are currently being introduced in pathology. Expand
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
  • R. Amado, M. Wolf, +9 authors David Chang
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy. Expand
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
TLDR
The results support the strategy of making these three active drugs available to all patients with advanced CRC who are candidates for such therapy to maximize OS and suggest that OS should no longer be regarded as the most appropriate end point by which to assess the efficacy of a palliative first-line treatment in CRC. Expand
...
1
2
...